Perimenstrual symptoms: prevalence and risk factors.

Logue, Camille M.; Moos, Rudolf H.

doi:10.1097/00006842-198607000-00002

Cited by 180 publications

(128 citation statements)

References 117 publications

(143 reference statements)

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…Biologic, social, demographic, and behavioral factors have been inconsistently associated with PMSx. 2,[9][10][11][12] High-sensitivity C-reactive protein (hs-CRP) is an acute phase inflammatory marker that has been associated with cardiovascular disease risk 13 and is an outcome associated with menopausal vasomotor symptoms. 14 It has also been associated with some of the risk factors for PMSx, such as smoking, depressive symptoms, increasing age, and increased body mass index (BMI).…”

mentioning

confidence: 99%

The Association of Inflammation with Premenstrual Symptoms

Gold

Wells

Rasor

2016

Journal of Women's Health

View full text Add to dashboard Cite

Background: About 80% of women experience premenstrual symptoms (PMSx), and about 50% of women seek medical care for them, posing a large medical care burden. However, despite women's use of antiinflammatory agents for relief from these symptoms, and the fact that anti-inflammatory agents provide relief from some PMSx, the relationship of inflammation to PMSx has not been well investigated. Methods: We, therefore, undertook the present cross-sectional analyses using baseline data from the longitudinal Study of Women's Health Across the Nation (SWAN), a racially/ethnically diverse cohort of midlife women (n = 2939), to determine if a biomarker of inflammation, high-sensitivity C-reactive protein (hs-CRP), was associated with PMSx. We performed factor analyses with Varimax rotations to determine five groupings of eight symptoms to develop a parsimonious set of outcome variables. We conducted backward stepwise multiple logistic regression models for each grouping, eliminating non-significant ( p > 0.05) covariates. Results: Having an hs-CRP level >3 mg/L was significantly positively associated with premenstrual mood symptoms (adjusted odds ratio [aOR] = 1.27, 95% confidence interval [95% CI] 1.02-1.58), abdominal cramps/ back pain (aOR = 1.40, 95% CI 1.09-1.80), appetite cravings/weight gain/bloating (aOR = 1.41, 95% CI 1.04-1.89), and breast pain (aOR = 1.26, 95% CI 1.02-1.55). Elevated hs-CRP level was not associated with premenstrual headaches or reporting three or more PMSx. Conclusions: The significant relationships of specific groups of PMSx with elevated hs-CRP levels have potential clinical implications for treatment and possibly for prevention by advising women about the factors associated with inflammation and the potential for treatment with anti-inflammatory agents.

show abstract

mentioning

confidence: 99%

The Association of Inflammation with Premenstrual Symptoms

Gold

Wells

Rasor

2016

Journal of Women's Health

View full text Add to dashboard Cite

show abstract

“…It is well-established that fluctuations in mood, energy, and physiological sensations can vary across the phases of the menstrual cycle, most specifically during the premenstrual, or late phase luteal, phase of the cycle (Altman et al, 1965;Gallant et al, 1991;Logue & Moos, 1986). This is important given that the present study seeks to measure emotion-specific reactivity.…”

Section: In Addition To Psychophysiological Responding Profile Of Momentioning

confidence: 97%

“…The reported changes can include vacillations in irritability, depressed mood, energy level, and physiological sensations (Logue & Moos, 1986). Importantly, most studies have associated increased physical and mental symptoms with the premenstrual, or late phase luteal, phase of the menstrual cycle (Altman, Knowles, & Bull, 1965;Gallant, Hamilton, Popeil, Morokoff, & Chakraborty, 1991).…”

Section: Psychophysiological Reactivity and The Menstrual Cyclementioning

confidence: 99%

Surface Facial Electromyography Reactions to Light-Relevant and Season-Relevant Stimuli in Seasonal Affective Disorder

Lindsey¹

2005

PsycEXTRA Dataset

View full text Add to dashboard Cite

Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. The original document contains color images. ABSTRACTFacial electromyography (EMG) activity was recorded from the zygomaticus major and corrugator supercilii muscle regions to examine emotion-specific reactivity in 24 currently depressed individuals meeting DSM-IV criteria for Major Depression, Recurrent with Seasonal Pattern, and no other current Axis I diagnosis, and 24 controls with normal mood and no history of depression. Based on models of seasonal affective disorder (SAD) and a proposed role for learned associations between depressive behavior and environmental stimuli signaling low light and winter season, participants were exposed to light-and season-relevant environmental stimuli and were asked to imagine what they would be feeling and thinking if they were actually in the picture. Skin conductance response was also assessed to determine participants' general sympathetic arousal to the stimuli. Results indicated that SAD participants: 1) responded to bright light stimuli with decreased corrugator mean EMG activity relative to low light stimuli; 2) demonstrated no increases in zygomatic mean EMG activity to bright light stimuli; 3) reported an exacerbation of baseline depressed mood following low light and winter stimuli and an improvement in depressed mood following bright light stimuli; and 4) evidenced increased SCR magnitude to bright light stimuli as compared to low light stimuli. Notably, corrugator and self-report mood ratings support previous findings of heightened psychophysiological reactivity and exacerbated depressed mood after exposure to light-relevant stimuli in SAD and suggest that light intensity may be more salient than seasonal cues in determining affective reactivity. Further research is needed to understand how these associations develop, and to establish the clinical implications for psychophysiological measures in SAD assessment and treatment monitoring. SUBJECT TERMS ACKNOWLEDGMENTS

show abstract

“…Among the nearly 150 reported cyclically recurrent emotional and somatic symptoms, the most common include irritability, fatigue, depression or mood swings, breast tenderness, bloating, and food cravings [1][2][3]. Approximately 3%-8% of reproductive-age women experience mood, behavioral and/or physical symptoms during the fi nal week of their menstrual cycle that are severe enough to meet the criteria for premenstrual dysphoric disorder (PMDD) [4][5][6].…”

mentioning

confidence: 99%

Pharmacotherapy for premenstrual dysphoric disorder: A meta-analysis of phase 3 trials

Yum

Ryu

Park

et al. 2012

Korean J Obstet Gynecol

View full text Add to dashboard Cite

Up to 80% of women experience physical and emotional changes that are related to their menstrual cycle. Among the nearly 150 reported cyclically recurrent emotional and somatic symptoms, the most common include irritability, fatigue, depression or mood swings, breast tenderness, bloating, and food cravings [1][2][3]. Approximately 3%-8% of reproductive-age women experience mood, behavioral and/or physical symptoms during the fi nal week of their menstrual cycle that are severe enough to meet the criteria for premenstrual dysphoric disorder (PMDD) [4][5][6]. PMDD is thought to result from the complex interaction among ovarian steroid production, endogenous opioid peptides, central neurotransmitters, prostaglandins, and peripheral autonomic and endocrine systems [7][8][9]. Of the wide range of medications available for this treatment approach, the most commonly used agents are oral contraceptives and antidepressants. As a clinician faced with patients who complain of premenstrual symptoms, it is difficult to predict which symptoms will benefit from treatment with which drug. In some cases, it is puzzling on the part of both patients and physicians whether premenstrual distress requires medical treatment at all. Often, patients read about alternative remedies advertised in beauty magazines, newspapers, television ads, the internet, and seek advice from friends and family. There is overwhelming amount of information on which underwear to wear, which foods to eat and avoid, special herbs, drinks, even lucky charms. In the midst of all the available remedies, one wonders what role medications can have in the competition. This paper aims to summarize and help readers understand the evidence, and ultimately help physicians make practical decisions about pharmacotherapy for PMDD. The primary objective of this review is to search for signals regarding the following questions: Premenstrual dysphoric disorder (PMDD) is a common condition that temporarily, but repetitively affects patient's global function. Patients and physicians alike are often uncertain whether prescription medication for PMDD is suffi ciently effective. The primary objective of this analysis is signal detection in effi cacy of pharmacological treatments in PMDD. Secondary objective is to review which symptoms are likely to respond to which medications. The review included otherwise healthy women with clinician confi rmed diagnosis of PMDD who participated in phase 3 clinical trials for the treatment of PMDD. Twelve pair-wise comparisons of drug and placebo for 2,420 patients with PMDD were performed. Oral contraceptives and selective serotonin receptor inhibitor were effective in alleviating symptoms of PMDD compared to placebo. Both Intermittent and continuous administration were more effective than placebo. This meta-analysis provides a signal that pharmacological treatment of PMDD is effective.

show abstract

Perimenstrual symptoms: prevalence and risk factors.

Cited by 180 publications

References 117 publications

The Association of Inflammation with Premenstrual Symptoms

The Association of Inflammation with Premenstrual Symptoms

Surface Facial Electromyography Reactions to Light-Relevant and Season-Relevant Stimuli in Seasonal Affective Disorder

Pharmacotherapy for premenstrual dysphoric disorder: A meta-analysis of phase 3 trials

Contact Info

Product

Resources

About